Positive FDA Pre-IND Feedback Announced for SVC112 Program in Advanced Solid Tumors
“We are very encouraged by the FDA’s feedback and believe this represents an important milestone in the development of SVC112,” said Antonio Jimeno, MD, PhD, CU Anschutz Professor, Medicine-Medical Oncology, and Board member of SuviCa. “The Agency’s responses support our development strategy and provide a clear regulatory path toward IND submission and initiation of our first-in-human clinical study, added Dr. Jimeno. “The innovative support network at the University of Colorado’s Boulder and Anschutz campuses has made all this possible,” said Tin Tin Su, PhD, CU Boulder Professor, lead inventor of SVC112, and co-founder of SuviCa.
Share:
More News
Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20
“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of
“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence
“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib